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Anti-inflammatory mechanisms of
IFN-γ studied in experimental
autoimmune encephalomyelitis
reveal neutrophils as a potential
target in multiple sclerosis
Nichole M. Miller, Jun Wang †, Yanping Tan and Bonnie N. Dittel *
BloodCenter of Wisconsin, Blood Research Institute, Milwaukee, WI, USA
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS)
mediated by T helper (h)1 and/or Th17 CD4 T cells that drive inflammatory lesion
development along with demyelination and neuronal damage. Defects in immune
regulatory mechanisms are thought to play a role in the pathogenesis of MS. While an
early clinical trial indicated that IFN-γ administration was detrimental to MS, studies in
the mouse model of MS, experimental autoimmune encephalomyelitis (EAE), indicated
that IFN-γ exhibits a number of anti-inflammatory properties within the CNS. These
mechanisms include inhibition of IL-17 production, induction of regulatory T cells, T cell
apoptosis and regulation of chemokine production. Mice deficient in IFN-γ or its receptor
were instrumental in deciphering the anti-inflammatory properties of IFN-γ in the CNS. In
particular, they revealed that IFN-γ is a major regulator of neutrophil recruitment into the
CNS, which by a variety of mechanisms including disruption of the blood-brain-barrier
(BBB) and production of reactive oxygen species are thought to contribute to the onset
and progression of EAE. Neutrophils were also shown to be instrumental in EAE relapses.
To date neutrophils have not been appreciated as a driver of MS, but more recently based
largely on strong EAE data this view is being reevaluated by some investigators in the
field.
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Introduction
Multiple sclerosis (MS) is an autoimmune disease driven by CD4 T cells of the T helper (h) 1
and/or Th17 subtype (Lovett-Racke et al., 2011). Once the pathogenic T cells enter the CNS they
execute an inflammatory cascade that results in the infiltration of immune cells into the CNS
from the periphery and the activation of local CNS antigen presenting cells, microglial cells, and
astrocytes. This inflammatory response leads to loss of oligodendrocytes resulting in demyelination
(Nylander and Hafler, 2012). It is now appreciated that neuronal damage/dysfunction starts
at early stages of MS (Nylander and Hafler, 2012). Inflammation is a multifaceted process
that requires cell-cell communication via cytokines and chemokines. The animal model of MS,
experimental autoimmune encephalomyelitis (EAE), has greatly assisted with the process of
deciphering the critical mediators of the inflammatory cascade that are important for CNS
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inflammation (McCarthy et al., 2012). The targeting of a number
of cytokines and chemokines and their receptors has shown
to alter EAE disease severity. One particular cytokine that has
garnered much interest is interferon (IFN)-γ. While IFN-γ
was first described in the context of viral infections, it quickly
became clear that it exhibited pro-inflammatory properties and
functioned more like an interleukin. While the root cause of
MS is not clear, dysregulation of immune regulatory genes is
thought to play amajor role (Nylander andHafler, 2012). In every
inflammatory response it is essential that anti-inflammatory
mechanisms must be turned on to avoid severe tissue damage
(Dittel, 2008). Many immune regulatory effector molecules
exhibit both pro- and anti-inflammatory functions (Dittel, 2008).
IFN-γ is such an effector molecule and once genetic ablation was
achieved in mice it was possible to unravel the anti-inflammatory
mechanisms at play in the EAEmodel (Kelchtermans et al., 2008).
Of particular interest to this review is that the pro-inflammatory
properties of IFN-γ are dispensable for EAE onset. Rather it
is the anti-inflammatory mechanisms that are the most critical
by attenuating the severity of EAE. While many mechanisms
have been proposed whereby IFN-γ exerts protection in EAE,
in this review we concentrate on its role in regulating T cell
subsets, apoptosis and suppressing neutrophil recruitment into
the CNS.While neutrophils have not historically been considered
a therapeutic target inMS, we believe that the prevailing evidence
suggests that this perspective should be revisited.
IFN-γ, a Pleiotropic Cytokine
In the early 1960s the existence of a soluble factor induced in
human leukocytes with mitogens with anti-viral activity was
known (Billiau and Matthys, 2009). In the early 1970s, it was
clear that two distinct forms of interferons existed with the
“classical interferons” termed Type I and the immune-induced
interferon Type II (Billiau and Matthys, 2009). It wasn’t until
1980 that the Type I interferons were named IFN-α and IFN-
β and the Type II named IFN-γ (Billiau and Matthys, 2009).
Today it is well established that IFN-γ’s activities as a cytokine
or interleukin are more important biologically than its anti-viral
effects. The IFN-γ receptor (IFNGR) is a heterodimer composed
of IFNGR1 and IFNGR2. IFN-γ ligand binding leads to receptor
oligomerization and activation of the receptor associated Janus
kinases (JAK) 1 and 2 that in turn phosphorylate the intracellular
domain of IFNGR1 recruiting signal transducer and activator of
transcription 1 (STAT1) (Ramana et al., 2002). The activation
of STAT1 by phosphorylation results in its dimerization and
translocation to the nucleus where it regulates gene transcription
of IFN-γ-regulated genes (Ramana et al., 2002). While the
primary producers of IFN-γ are T lymphocytes and natural killer
(NK) cells, its receptor is expressed by virtually all cell types
(Ramana et al., 2002; Platanias, 2005; Billiau and Matthys, 2009).
Biological activities of IFN-γ are broad and include:
macrophage activation, upregulation of major histocompatibility
complex (MHC) class I and II molecules, upregulation of
antigen processing and presentation machinery, T helper (Th)
1 commitment of naïve CD4 T cells, inhibition of cell growth,
apoptosis, regulation of leukocyte-endothelial interactions, and
immunoglobulin isotype class switching, among other functions
(Saha et al., 2010; Akdis et al., 2011). Thus, IFN-γ is a major
contributor to both innate and adaptive immune responses.
Mice deficient in either IFN-γ or the IFNGR1 subunit exhibit no
developmental defects including normal hematopoiesis (Dalton
et al., 1993; Huang et al., 1993). While mice lacking the IFNGR
had normal cytotoxic and Th responses they exhibited increased
susceptibility to L. monocytogenes and vaccinia virus (Huang
et al., 1993). The same study also revealed the requirement for
IFN-γ in IgG2a production (Huang et al., 1993). IFN-γ-deficient
mice were similar and were shown to have impaired macrophage
activation, increased mitogen induced splenocyte proliferation,
enhanced T cell cytolysis, and decreased NK cell activity (Dalton
et al., 1993). Defective expression of the IFNGR in humans
results in early susceptibility to mycobacterial infections (Zhang
et al., 2008).
Administration of IFN-γ Exacerbated
Multiple Sclerosis
Autoimmunity occurs when the immune system inappropriately
targets self-tissue as foreign mounting an immune attack leading
to extensive tissue damage that can lead to death. Autoimmunity
can target any tissue or organ system and represents a large
burden on the medical system with over 23 million Americans
being affected. In addition, autoimmunity is one of the top
10 leading causes of death in women (Autoimmune Diseases
Coordinating Committee, 2002). Multiple sclerosis (MS) is
an autoimmune disease manifested in the central nervous
system (CNS) that is considered both a demyelinating and
neurodegenerative disease (Nylander and Hafler, 2012). The
prevailing view is that CD4+ T cells are the initial drivers of
inflammation in MS. In early studies using the animal model of
MS, experimental autoimmune encephalomyelitis (EAE), IFN-γ
producing Th1 cells were considered the pathogenic immune cell
(Lovett-Racke et al., 2011).
Given that IFN-γ exhibits many immunoregulatory properties
and since MS patients were reported to be deficient in its
production a small clinical trial was performed to determine
whether the administration of IFN-γ would be therapeutic
(Neighbour et al., 1981; Vervliet et al., 1983; Panitch et al., 1987;
Panitch, 1994). The results were unequivocal that IFN-γ therapy
was not suitable for the treatment of MS given that it exacerbated
disease. Fortunately, the patients completely recovered from the
attacks (Panitch et al., 1987; Panitch, 1994). This result has set
back future clinical trails targeting IFN-γ or its pathways even
though, as discussed below, strong experimental data in EAE
suggests that it functions as a potent anti-inflammatory mediator
of CNS inflammation.
Experimental Evidence in EAE that IFN-γ is
anti-inflammatory
Shortly after the MS IFN-γ clinical trail was reported EAE results
examining the role of IFN-γ were observed in both the C57BL/6J
and SJL/J models of EAE induced by immunization with spinal
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cord homogenate. Specifically, neutralizing antibody to IFN-γ
increased both morbidity and mortality (Billiau et al., 1988).
Conversely, systemic administration of IFN-γ reduced morbidity
and mortality (Billiau et al., 1988). Similar findings were reported
in the Lewis rat where systemic IFN-γ administration did
not alter EAE induced by immunization with spinal cord
homogenate, but suppressed disease when administered into the
CNS ventricular system (Voorthuis et al., 1990). Furthermore,
systemic administration of anti-IFN-γ just prior to disease onset
exacerbated disease, while a single dose of IFN-γ given on
day 8 of disease was sufficient to suppress disease (Voorthuis
et al., 1990). In SJL/J mice the mild EAE that occurs following
immunization with myelin basic protein (MBP) was greatly
exacerbated following administration of two doses of anti-IFN-
γ (Duong et al., 1992). When passive EAE was induced in
SJL/J mice by the adoptive transfer of lymphocytes from MBP-
challenged mice, anti-IFN-γ also resulted in severe EAE (Duong
et al., 1992). Interestingly, while administration of anti-IFN-γ on
day 0 drove more severe disease when given at later timepoints
(day 7, 14, or 21) in the immunizationmodel there was no impact
on disease severity (Duong et al., 1992). Similar findings were
observed in passive EAE (Duong et al., 1992). In a follow up
study, this same group showed that anti-IFN-γ potentiated the
development of EAE in a number of resistant mouse strains
following immunization with MBP. In contrast to the human
IFN-γ clinical trial, collectively the murine studies indicate that
IFN-γ plays a protective role in EAE particularly early in disease
likely due to effects in the periphery. In humans, IFN-γ was
administered well after the onset of MS suggesting that in later
stages of disease IFN-γ is a driver of disease perhaps via CNS
specific mechanisms.
Once mice deficient in IFN-γ and its receptor were generated,
the above EAE studies were repeated with similar findings. For
the IFN-γ-deficient experiments the knockout was backcrossed
onto the B10.PL susceptible strain. When EAE was induced by
immunization with guinea pig MBP disease onset was similar in
+/+ and −/− littermate controls, but while the WT underwent
recovery the knockout mice exhibited a high mortality rate
(Ferber et al., 1996) (Table 1). For the IFNGR-deficient study
the mice used were the EAE resistant 129/Sv mouse strain.
Upon immunization with the human myelin oligodendrocyte
glycoprotein (MOG)35−55 peptide, EAE occurred in 100% of the
deficient animals (Willenborg et al., 1996) (Table 1). In passive
EAE, while both the +/+ and −/− littermates were equally
susceptible to EAE, only the knockout mice exhibited mortality
(Willenborg et al., 1999) (Table 1). A similar finding indicating
that IFN-γ conferred resistance to EAE was also reported in IFN-
γ−/− BALB/c mice (Krakowski and Owens, 1996) (Table 1). The
above studies clearly demonstrated that IFN-γ plays a protective
role in EAE initiating a multitude of subsequent studies focused
on specific mechanisms.
Influence of IFN-γ on the Effector CD4 Th
Phenotype
Naïve CD4 T cells are plastic and with the provision of specific
cytokine stimuli differentiate into unique Th subsets. The
quintessential pathways are Th1, Th2, and more recently Th17.
Th1 cells require IL-12 signaling and express IFN-γ in the
absence of IL-4 production. While IL-12 is not required for
the induction of EAE, its administration at disease initiation,
but not onset, was shown to suppress EAE via the induction
of IFN-γ (Zhang et al., 2003; Gran et al., 2004). Th2 cells
express IL-4 and also require it for differentiation. Th2 cells are
not encephalitogenic and interestingly their differentiation is
blocked by IFN-γ. We have shown that IL-4 production within
the CNS is protective during EAE. However, whether IFN-γ
downregulates CNS derived IL-4 is not known (Ponomarev et al.,
2007a). More recently, CD4 T cells that produce IL-17 have been
described with encephalitogenic potential (Lovett-Racke et al.,
2011). IL-17 production by CD4 T cells requires TGF-β and IL-6
signals and expression of the transcription factor RORγt. IFN-γ
has been shown to inhibit IL-17 production by CD4 T cells and
in its absence Th17 cells are increased in the CNS during EAE
(Harrington et al., 2005; Park et al., 2005; Berghmans et al., 2011).
However, IL-17 is not an essential cytokine for the induction or
progression of EAE (Komiyama et al., 2006). Along with our
colleagues, we showed that the critical cytokine produced by
both Th1 and Th17 cells for the induction of EAE is GM-CSF
(Ponomarev et al., 2007b; El-Behi et al., 2011). As with IFN-γ,
GM-CSF is also a pleiotropic cytokine that can influence EAE
induction by a variety of mechanisms including activation of
antigen presenting cells, enhancement of pro-inflammatory
cytokine production and promotion of leukocyte adhesion and
chemotaxis (Shiomi and Usui, 2015). In addition, GM-CSF can
circumvent negative regulation by IFN-γ by inhibiting STAT1
tyrosine phosphorylation with the net result being reduced
IFN-γ-induced gene transcription (Kasper et al., 2007). Thus, by
controlling the phenotype of naïve T cells with encephalitogenic
potential IFN-γ influences the initiation and severity
of EAE.
Influence of IFN-γ on the Regulatory CD4
phenotype
It is well established that an important tolerance mechanism
keeping autoimmune responses in check are CD4 T cells that
express the transcription factor Foxp3. Mice and humans with
mutations in Foxp3 quickly succumb to a lethal autoimmune
syndrome (Bennett et al., 2001; Brunkow et al., 2001;Wildin et al.,
2001; Fontenot et al., 2003; Hori et al., 2003). CD4+Foxp3+ T
regulatory cells (Treg) that develop in the thymus are termed
natural (n) Treg (Fontenot et al., 2003; Hori et al., 2003). Treg
can also be induced (i) in the periphery in the presence of
TGF-β and IL-2 (Chen et al., 2003; Davidson et al., 2007). In
EAE, Treg have been shown to strongly inhibit both the onset
and progression of disease (Kohm et al., 2002; McGeachy et al.,
2005; Gultner et al., 2010; Ray et al., 2012). IFN-γ does not
seem to influence nTreg development given that IFNGR−/−
mice were shown to harbor normal numbers of functional
Treg (Kelchtermans et al., 2005). Rather IFN-γ promotes iTreg
conversion by inducing Foxp3 expression generating iTreg with
the capacity to suppress the severity of EAE (Wang et al.,
2006).
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TABLE 1 | Summary of EAE disease susceptibility and presentation in various mouse strains deficient in IFN-γ or its receptor.
Mouse straina EAE mouseb EAE inductionc EAE disease References
B10.PL; susceptible IFN-γ–/– Active: guinea pig MBP Severe with high mortality Ferber et al., 1996
129/Sv; resistant IFNGR–/– Active: human MOG35−55 High susceptibility, severe disease Willenborg et al., 1996
129/Sv; resistant IFNGR–/– Passive: human MOG35−55 High mortality
Willenborg et al., 1999
BALB/c; resistant IFN-γ–/– Active: bovine MBP High susceptibility, severe disease Krakowski and Owens,
1996
BALB/c; resistant IFN-γ–/– Passive: MBP exon 2 High susceptibility, high atypical disease Abromson-Leeman
et al., 2004
MBP-TCR B10.PL, susceptible IFN-γ–/–Rag2–/– Spontaneous, mouse MBPAc1−11 Atypical Wensky et al., 2005
B10.PL; susceptible IFN-γ–/– Passive: mouse MBPAc1−11 Classical Wensky et al., 2005
a Indicates the mouse strain in which EAE was induced and whether the WT mouse is susceptible to EAE.
b Indicates the gene deficiency status of the mouse in which EAE was induced.
c Indicates whether EAE was induced by active immunization with the antigen used indicated or by passive induction by the adoptive transfer of encephalitogenic T cells with their
specificity indicated.
IL-27 also induces a Treg phenotype that were shown to be
distinct from the iTreg induced by IFN-γ (Hall et al., 2012). These
cells termed Tr1 express IFN-γ and high levels of IL-10 and play
an important role in controlling local inflammation induced by
Th1 cells, particularly during Toxoplasmosis and Leishmaniasis
(Anderson et al., 2007; Jankovic et al., 2007; Hall et al., 2012). IL-
10 is a potent anti-inflammatory cytokine that has been shown to
be suppressive in EAE (Bettelli et al., 1998). Tr1 cells generated
in vitro with IL-27 and IL-12 stimulation from MOG35−55
immunized mice exhibited less encephalitogenic potential as
compared to CD4+ T cells stimulated in IL-12 alone (Apetoh
et al., 2010). In addition to generating Tr1 cells, CD27 can also
potentially limit EAE severity by blocking Th17 development
(Fitzgerald et al., 2007; Diveu et al., 2009; Sweeney et al., 2011).
IL-27 was shown to block Th17 development by suppressing
RORγt expression in a STAT1-dependent manner (Diveu et al.,
2009). Interestingly, MS patients that do not respond to IFN-β
therapy were shown to produce lower levels of IL-27 following
stimulation with IFN-β than the responder patients (Sweeney
et al., 2011). Thus, IL-27 production is an important negative
regulator of CNS inflammation by inducting Tr1 cells that
express the anti-inflammatory cytokines IL-10 and IFN-γ, while
limiting Th17 cell generation.
Role for IFN-γ in Controlling T Cell
Apoptosis
In 1990 IFN-γ was implicated in T cell death in a study
showing that anti-IFN-γ blocked the death of a cloned Th1 cell
line stimulated via the TCR in the absence of co-stimulation
(Liu and Janeway, 1990). From a number of studies, it is
clear that limiting the number of encephalitogenic CD4 T
cells within the CNS can either prevent or greatly reduce the
severity of EAE. This has been clearly demonstrated in IFN-
γ−/− mice, which were shown to have a significant increase in
the number of activated CD4 T cells 21 days following EAE
induction (Chu et al., 2000). These T cells were undergoing
increased proliferation and decreased apoptosis, demonstrating
an in vivo a role for IFN-γ in the induction of CD4 T cell
apoptosis (Chu et al., 2000). Subsequent studies demonstrated
that the proapoptic effects of IFN-γ could be mediated by the
induction of caspase-1 by the interferon regulatory factor (IRF)-1
transcription factor in a STAT1-dependent manner (Chin et al.,
1997). Conversely, caspase-1 plays a role in EAE pathogenesis
by cleaving pro-IL-1β as a component of the nucleotide-binding
oligomerization-like receptor family, pyrin domain containing
3 (NLRP3) inflammasome. IL-1β can regulate EAE by several
mechanisms. First, it can upregulate VCAM-1 expression by
endothelial cells, which is a ligand for VLA-4 an essential integrin
required for CD4 T cell migration into the CNS (Baron et al.,
1993). It was recently shown that CD4+ T cells require priming
by NLRP3 inflammasome-sufficient antigen presenting cells to
obtain the ability to migrate into the CNS via upregulation
of specific chemokine receptors (Inoue et al., 2012). A second
important mechanism for IL-1β is its promotion of IL-17
production by CD4 and γδ T cells in synergy with IL-6 and
IL-23 (Chung et al., 2009; Lalor et al., 2011). In addition to its
effects on CD4 T cells, caspase-1 also plays a detrimental role
in oligodendrocyte injury and demyelination (Ren et al., 2011;
Loda and Balabanov, 2012). Thus, IFN-γ via its upregulation
of caspase-1 plays both protective and pathogenic roles in CNS
inflammation.
In addition, IFN-γ has the capacity to influence
Fas-dependent cell death by increasing the surface expression
of Fas, also in a STAT1-dependent manner (Xu et al., 1998).
Interestingly, in the later study, IFN-γ-induced cell death was
inhibited by caspase 1 inhibitors (Xu et al., 1998). We, and others,
have clearly demonstrated a role for Fas expression within the
CNS for the onset of EAE (Dittel et al., 1999; Sabelko-Downes
et al., 1999; Dittel, 2000). In addition, FasL expression by
encephalitogenic T cells was shown to play a pathogenic role in
EAE induction (Dittel et al., 1999; Sabelko-Downes et al., 1999;
Dittel, 2000). However, in our study, we did not find a role for
Fas expression by the encephalitogenic T cells in regulating the
severity of EAE (Dittel et al., 1999). A subsequent study using
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conditional knockout mice with an oligodendrocyte deficiency
in Fas, demonstrated its role in inducing demyelination
(Hovelmeyer et al., 2005).
An additional mechanism whereby IFN-γ can induce T
cell death is via the induction of indoleamine 2,3 dioxygenase
(IDO) in dendritic cells (Mellor and Munn, 2004). Through its
degradation of tryptophan, an essential amino acid required for
T cell proliferation, IDO promotes T cell death (Mellor and
Munn, 2004). A number of studies have demonstrated IDO
expression in the CNS in astrocytes and microglia/macrophages
and its importance in the suppression of EAE (Sakurai et al.,
2002; Kwidzinski et al., 2003, 2005; Yan et al., 2010). Tryptophan
metabolites generated by IDO have been shown to promote Treg
generation, which is an additional mechanism whereby IFN-γ
controls CD4 T cell phenotypes (Yan et al., 2010).
The Role of IFN-γ Inducible Chemokines in
EAE
In 1998 Drs. Karpus and Ransohoff wrote an insightful
commentary suggesting that temporal and spatial chemokine
expression in the CNS during EAE governed disease pathogenesis
(Karpus and Ransohoff, 1998). Evidence supporting this
hypothesis will be discussed. Largely by the use of chemokine
receptor knockout mice, the role for specific chemokines in
the more severe disease observed in mice deficient in IFN-
γ signaling has been revealed. As discussed above, IFN-γ can
promote the migration of T cells into the CNS by upregulating
chemokine receptors and adhesion molecules. In addition, IFN-γ
can influence cell migration into the CNS by either upregulating
or inhibiting specific chemokine production.
Two IFN-γ-inducible chemokines that were hypothesized to
be involved in EAE initiation and severity are CXCL9 (MIG) and
CXCL10 (IP-10) (Karpus and Ransohoff, 1998). Both chemokines
along with CXCL11 (I-TAC), which is also IFN-γ-inducible,
share CXCR3 as their receptor, which is preferentially expressed
by Th1 cells (Sallusto et al., 1998). Differential expression of
CXCR3 by Th17 cells has been reported and may depend on
whether they also produce IFN-γ (Jadidi-Niaragh andMirshafiey,
2011). CXCL9, CXCL10, and CXCL11 have been shown to be
upregulated in the CNS during EAE, in a manner consistent
with IFN-γ production by Th1 encephalitogenic T cells (Carter
et al., 2007; Kroenke et al., 2008). In EAE, while CXCR3−/− mice
exhibited more severe EAE there was no alteration in the gross
quantitative and qualitative nature of the inflammatory infiltrates
(Liu et al., 2006;Muller et al., 2007). However, CD4+Foxp3+ Treg
were shown to be reduced in the white matter of CXCR3−/−mice
(Muller et al., 2007). CNS tissues fromCXCR3−/−mice exhibited
more severe blood-brain-barrier (BBB) disruption and reduced
levels of IFN-γ in the serum and spinal cord (Liu et al., 2006). A
role for CXCL9 has not been carefully examined in EAE. CXCL10
has been shown to be pathogenic in EAE in several studies that
neutralized CXCL10 with blocking antibodies (Fife et al., 2001;
Narumi et al., 2002). In contrast, in later studies neither anti-
CXCL10 nor a global deficiency in CXCL10 resulted in more
severe EAE (Klein et al., 2004; Tsunoda et al., 2004; Byrne et al.,
2009). However, CXCL10−/− mice were more susceptible to
EAE onset when induced with subthreshold levels of MOG35−55
(Klein et al., 2004). The above cumulative studies suggest that
CXCL9 and CXCL10 are not critical cytokines in the induction
of EAE and in the most recent study examining this issue EAE
severity induced by MOG35−55 immunization was not altered
in CXCR3−/− or CXCL10−/− mice (Lalor and Segal, 2013).
C57BL/6 mice do not produce functional CXCL11 so its role
in EAE was investigated using CXCL11-Ig that upon adoptive
transfer suppressed EAE (Zohar et al., 2014). CXCL11 is thought
to be protective in EAE via the induction of Tr1 regulatory T
cells (Zohar et al., 2014). CXCL10-Ig had no effect (Zohar et al.,
2014). Further evidence for a protective role for CXCL11 was
demonstrated using as CXCR3 receptor antagonist composed
of a truncated CXCL11(4-79) (Kohler et al., 2008). Thus, there
is little evidence that IFN-γ-inducible chemokines play a major
pathogenic role in EAE. This is likely due to redundancy in
the chemokine family whereby encephalitogenic T cells can
utilize chemokine receptors other than CXCR3 to migrate
into the CNS.
IFN-γ Regulates the EAE Clinical
Phenotype
One of the first reports to examine chemokine production in
mice deficient in IFN-γ reported that CCL2 (MCP-1) and CXCL1
(Gro-α), but not CXCL10 were expressed in the CNS (Glabinski
et al., 1999). The next year, Tran et al., addressed the same
question and found that CCL5 (RANTES) and CCL2 were not
detectable in the CNS of IFN-γ−/− or IFNGR−/− mice with EAE
(Tran et al., 2000). In contrast, CXCL2 (MIP2β, GRO-β) and
CCL1 (TCA-3) were upregulated in the same mice. Both of the
later chemokines attract neutrophils, which is consistent with a
predominance of Gr-1+ neutrophils in the CNS of both IFN-
γ−/− and IFNGR−/− mice with EAE (Tran et al., 2000). It is
now known that Gr-1 antibodies recognize Ly6C expressed by
monocytes/macrophages and neutrophils and Ly6G expressed by
neutrophils. Thus, Gr-1 recognition over estimated the number
of neutrophils in the lesions. However, H&E staining did indicate
an increased presence of cells with a PMN morphology in both
IFN-γ−/− and IFNGR−/− mice with EAE (Willenborg et al.,
1996; Tran et al., 2000).
It is now well established that a deficiency in IFN-γ or its
receptor has a profound effect on the nature of the EAE disease
course. Classical EAE in WT presents as an ascending paralysis
with inflammatory lesions in the white matter of the spinal cord
(Cross et al., 1993). Non-classical or atypical disease presents
with distinct clinical signs consisting of a slight head tilt that
progresses to a severe head tilt or with the mouse laying on its
side, which subsequently leads to spinning or an axial rotatory
motion (Abromson-Leeman et al., 2004; Wensky et al., 2005).
This atypical disease was associated with predominate lesions in
the brain, cerebellum and brainstem (Abromson-Leeman et al.,
2004; Wensky et al., 2005) (Table 1). The first report of atypical
disease was observed in Balb/c IFN-γ−/− mice immunized
with MBP peptides (Abromson-Leeman et al., 2004). Lesions
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in both the classical and atypical EAE contained neutrophils
as determined by histology (Abromson-Leeman et al., 2004)
(Table 1). EAE induced by adoptive transfer indicated a role
for the encephalitogenic T cell in determining whether disease
presented as classical or atypical (Abromson-Leeman et al.,
2004) (Table 1). The second report describing atypical disease
utilized transgenic B10.PL mice bearing a TCR specific for
myelin basic protein (MBP) (MBP-TCR), which succumb to
spontaneous EAE with a 100% penetrance when crossed to
Rag1−/− mice (Goverman et al., 1993; Wensky et al., 2005). As
in earlier reports, mice lacking IFN-γ−/− had a prominence of
granulocytes in the CNS lesions (Wensky et al., 2005). In the
same study, EAE induced by the adoptive transfer of Th1 MBP-
TCR T cells into IFN-γ−/− mice resulted in classical disease,
supporting the notion that encephalitogenic T cells play an
essential role in determining the nature of EAE disease (Wensky
et al., 2005). This was further explored in two studies published
in 2008, which specifically compared a role for Th1 and Th17
encephalitogenic T cells using adoptive transfer. In the first study,
Th17 skewed encephalitogenic T cells induced predominantly
atypical EAE with Th1 driving classical disease (Stromnes et al.,
2008). Furthermore, it was concluded that it was not the number
of Th17 cells that drove brain lesions, but their predominance
over Th1 cells that was important (Stromnes et al., 2008). A
specific role for IL-17 production was indicated by the loss of
inflammatory lesions in the brain parenchyma, but not spinal
cord, upon injection of anti-IL-17 (Stromnes et al., 2008). The
ratio of Th1:Th17 was shown to be important in determining
lesion localization with the conclusion that inflammation in the
brain parenchyma occurred when Th17 were more prevalent
leading to a disproportionate increase in IL-17 in the brain
(Stromnes et al., 2008). Of interest, anti-IL-17 also reduced
neutrophil infiltration in the spinal cord. In a second study, it
was also found that increasing numbers of Th17 T cells was not
sufficient to drive atypical EAE (Lees et al., 2008). In addition,
IFN-γ−/− encephalitogenic T cells were shown to predominantly
induce classical disease indicating that IFN-γ production by
T cells is not the driving factor in regional localization (Lees
et al., 2008). While granulocyte infiltration was not specifically
examined, an increase in CXCL2 was observed in the spinal cord
of mice with severe Th1 disease as compared to the cerebellum
(Lees et al., 2008).
IFN-γ Regulation of EAE Occurs in both the
CNS and Peripheral Immune Cells
A limiting factor of the use of global knockouts is that they did
not allow the discrimination of whether the IFN-γ target were
cells within the CNS or periphery. This question was addressed
by the generation of bone marrow (BM) chimeras and cell
specific deficiencies. The chimera strategy was utilized first by
transplanting IFNGR−/− BM intoWTmice (IFNGR−/− →WT)
generating mice in which only the peripheral immune system
lacks IFN-γ signaling. In the reverse chimera (WT→IFNGR−/−)
because CNS resident cells including microglial cells do not turn
over after transplantation the CNS along with non-hematopoeitic
peripheral cells are deficient in the IFNGR (Ponomarev et al.,
2005). In the first study to utilize this strategy, encephalitogenic
T cells were derived from MOG35−55 immunized IFNGR−/−
mice (Willenborg et al., 1999). The authors concluded that
IFNGR regulation occurred in both the hematopoietic lineage
and in the host tissues with no discussion of atypical disease
(Willenborg et al., 1999). A second study utilizing an identical
approach except that WT encephalitogenic T cells were used
came to the same conclusion with the addition that both chimeras
exhibited atypical disease, which was more prevalent in the
IFNGR−/−→WT chimeras (Lees et al., 2008). The opposite
result was observed in a third study whereby atypical disease was
more prevalent in WT→IFNGR−/− chimeras (Lee et al., 2012).
The reason for the difference in results is not clear, but since
EAE was induced by immunization with MOG35−55 in the later
study the encephalitogenic T cells were not equivalent in regards
to IFN-γ responsiveness, which could influence whether they are
more Th1- or Th17-like (Lee et al., 2012). We addressed the issue
of the IFN-γ-responsive cell in our own studies whereby EAE
was induced in BM chimeras by adoptive transfer of WT MBP-
TCR encephalitogenic T cells (Dittel et al., 1999; Ponomarev
et al., 2005). We found that IFNGR−/−→WT chimeras exhibited
progressive disease (Figure 1A), while no difference in the EAE
disease course was observed in the WT→IFNGR−/− chimeras
(Figure 1B) as compared to control WT chimeras. Atypical
disease was observed only rarely in our studies (data not shown).
From our studies, we conclude that the IFN-γ-responsive cell
regulating typical EAE resides within the peripheral immune
system.
One drawback to the WT→IFNGR−/− chimeras is that
a deficiency in IFN-γ responsiveness is not restricted to the
CNS, thus it is possible that IFN-γ regulates EAE severity
and regionalization from the periphery. To circumvent that
issue transgenic mice were generated with a signaling defective
dominant-negative IFNGR specifically in astrocytes (Hindinger
FIGURE 1 | A deficiency in the IFNGR in the peripheral immune system,
but not the CNS, leads to severe EAE. B10.PL IFNGR−/− mice were
generated by crossing C57BL/6 IFNGR−/− mice to B10.PL for two
generations and then intercrossing. BM chimera mice were generated by
transplanting either WT (A,B), IFNGR+/+ (A) or IFNGR−/− (B) littermates with
donor BM from either WT (A,B) or IFNGR−/− (A) mice as described
(Ponomarev et al., 2005). EAE was induced by the adoptive transfer of WT
1× 106 MBP-TCR encephalitogenic T cells as described (Dittel et al., 1999).
EAE was scored daily on a five point scale: 0-no disease, 1-tail weakness,
1.5-hind limb ataxia, 2-hind limb paresis, 2.5-one hind limb paralyzed, 3-both
hind limbs paralyzed, 4-hind and forelimbs paralyzed, 5-death. The data are
the mean daily score from two experiments. ***p < 0.001 by the
Mann-Whitney test.
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et al., 2005, 2012). When EAE was induced by immunization
with MOG35−55, the transgenic mice exhibited a chronic slightly
progressive disease as compared to WT mice with no mention
of atypical disease (Hindinger et al., 2012). Further analysis
implicated a role for IFN-γ in dampening astrocyte activation
that could limit their production of chemokines and pro-
inflammatory cytokines (Hindinger et al., 2012). A second
approach to the same question silenced IFNGR signaling in
either astrocytes or microglial cells using lentiviral vectors that
expressed IFNGR1-specific shRNA using GFAP and CD11b to
drive their expression, respectively. The lentiviral vectors were
i.c.v. injected 3 days prior to EAE induction by immunization
with MOG35−55 (Ding et al., 2015). When the IFNGR was
silenced in astrocytes, EAE severity was significantly decreased
and was accompanied by decreased immune cell infiltrates (Ding
et al., 2015). A similar result was obtained in both Th1 and Th17
adoptive transfer EAE (Ding et al., 2015). The administration
of the GFAP silencing vector after disease onset also attenuated
disease severity (Ding et al., 2015). It was speculated that the
difference in outcome between the two astrocyte-focused studies
was due to the dominant-negative receptor serving as an IFN-
γ sink limiting its availability to negatively regulate EAE via
other cell types (Ding et al., 2015). When CD11b+ cells were
silenced, EAE was more severe with no mention of atypical
EAE (Ding et al., 2015). While the authors contributed this to
silencing in microglial cells, they did not definitively rule out
a role for peripheral immune CD11b+ cells in the negative
regulation (Ding et al., 2015). Cumulatively, the above studies
indicate that both CNS resident and peripheral immune cells play
a role in IFN-γ-mediated regulation of EAE and that atypical
EAE is variable depending upon the EAE disease model.
Neutrophils are Essential Drives of EAE
pathogenesis
In the articles discussed above one recurrent theme in mice
deficient in IFN-γ or its receptor is the presence of granulocytes
and an increase in chemokines that recruit them termed
ELR+ CXC chemokines. An essential role for granulocytes
was demonstrated by a dramatic reduction in EAE incidence
induced by either active immunization or adoptive transfer in
mice treated with anti-Gr-1 (RB6-8C5) or with anti-Ly6G (1A8)
(McColl et al., 1998; Carlson et al., 2008; Steinbach et al., 2013).
CXCL1 and CXCL2 are prototypic ELR+ CXC chemokines that
bind CXCR2 expressed by granulocytes. EAE induced in SJL/J
mice with proteolipid protein (PLP)139−151 led to a significant
increase in CXCL1 and CXCL2 in the spinal cord as early
as day 8–9 following immunization, which coincided with the
appearance of CXCR2+ cells (Carlson et al., 2008). An essential
role for CXCR2+ cells in EAE induction was demonstrated by
reduced EAE following antibody blocking or complete protection
from disease with genetic ablation of CXCR2 (Carlson et al.,
2008). The transfer of CXCR2+ cells into CXCR2−/− mice was
sufficient to restore EAE susceptibility (Carlson et al., 2008).
It was concluded that granulocytes drove disease by disruption
of the blood-brain-barrier (BBB) without altering peripheral T
cell responses (McColl et al., 1998; Carlson et al., 2008; Christy
et al., 2013; Steinbach et al., 2013). An alternative mechanism
whereby granulocytes attenuate EAE was speculated to be the
induction of iNOS in macrophages/neutrophils (Gr-1hi) by T
cell-derived IFN-γ that in turn suppressed T cell proliferation.
However, this has not been confirmed in vivo within the CNS
(Willenborg et al., 1999; Zehntner et al., 2005). Neutrophils have
also been implicated in thematuration of APCwithin the CNS via
their production of pro-inflammatory cytokines (Steinbach et al.,
2013).
Interestingly, granulocyte depletion also inhibited EAE onset
in IFNGR−/− mice (McColl et al., 1998). In back-to-back papers
the Segal and Goverman laboratories tied together regional
production of ERL+ CXC chemokines and the penetrance of
atypical EAE (Simmons et al., 2014; Stoolman et al., 2014). In
the Segal paper, atypical EAE in C57BL/6 IFNGR−/− mice was
associated with the upregulation of CXCL2 in the brainstem
and the recruitment of neutrophils into the site in a CXCR2-
dependent manner (Stoolman et al., 2014). In classical EAE in
WT mice, CCL2 was increased in the spinal cord driving the
recruitment of monocytes/macrophages in a partially CCR2-
dependent manner (Stoolman et al., 2014). Given that IL-17
induces CXCL2 the conclusion that atypical EAE was IL-17-
independent is an important finding (Iwakura et al., 2011;
Stoolman et al., 2014). In the Goverman study using C3HeB/FeJ
mice deficient in either IFNGR or IL-17RA, it was shown that
IL-17 promoted ELR+ CXC chemokine-mediated recruitment
of neutrophils into the brain while IFN-γ inhibited ELR+ CXC
chemokine and neutrophil production in the brain, but had the
converse effect in the spinal cord (Simmons et al., 2014). In
C3HeB/FeJ mice, IL-17 was shown to play a more prominent role
in driving atypical disease (Simmons et al., 2014).
The above Segal and Goverman studies utilized global
knockout mice thus it was not possible to discern the location
of the IFN-γ-responsive cell regulating neutrophil migration
into the CNS. This question is best addressed in IFNGR−/−
chimeras or mice with a cell-specific deficiency in the IFNGR.
Because Gr-1 recognizes both Ly6C and Ly6G, only those
papers identifying neutrophils using Ly6G are discussed. When
IFNGR signaling was inhibited in a dominant negative manner
leading to chronic EAE, no difference in neutrophil numbers
was detected in either the acute or chronic phase of disease
(Hindinger et al., 2012). Likewise, in the paper by Lee and
colleagues in which the classical disease scores were similar
in all four chimeras (WT→WT, IFNGR−/−→IFNGR−/−,
WT→IFNGR−/−, IFNGR−/−→WT) there was no difference
in the number of infiltrating neutrophils in the CNS. When
we addressed this question in our chimera system in which
IFNGR−/−→WT chimeras exhibit chronic progressive EAE
(Figure 1A), we did not observe a difference in the total number
of mononuclear cells (Figure 2A), CD4+ T cells (Figure 2B)
or CD11b+ myeloid cells (Figure 2C) on day 10 (onset), 15
(peak) or 21 (recovery) after EAE induction in the two chimeras.
However, when we observed the light scatter profiles an increase
in high SSC cells consistent with granulocytes was evident
in the IFNGR−/−→WT chimeras as compared to WT→WT
chimeras (Figure 2D). We then utilized Ly6C and Ly6G to
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FIGURE 2 | Mice deficient in the IFNGR in the peripheral immune
system do not have increased numbers of mononuclear, CD11b+
or CD4+ cells in the CNS during EAE, but have significant
increases in neutrophils and macrophages. BM chimera mice were
generated by transplanting WT mice with donor BM from either WT
(WT→ WT) or IFNGR−/− (IFNGR−/−→WT) mice as described
(Ponomarev et al., 2005). On days 10, 15, and 21 after EAE induction
total mononuclear cells were isolated and counted on a hemacytometer
and subsequently analyzed by flow cytometry for CD45 (total
mononuclear cells) (A), CD4 (CD45+CD11b−CD4+) (B), CD11b
(CD45+CD11b+) (C), neutrophils (CD11b+Ly6C+Ly6G+) (F), microglial
cells and resident macrophages (CD11b+Ly6CloLy6G−) (G) or
inflammatory macrophages (CD11b+Ly6ChiLy6G−) (H) (Ponomarev et al.,
2005). Each time point is the mean ± SD of three experiments with
pooled cells from 2 to 4 mice. Representative FSC and SSC light scatter
profiles (D) and counter plots of CD11b-gated cells for expression of
Ly6C and Ly6G (E) on days 10, 15, and 21 are shown for WT→ WT
and IFNGR−/−→WT chimeras.
differentiate monocytes/macrophages (CD11b+Ly6C+Ly6G−)
and neutrophils (CD11b+Ly6C+Ly6G+) (Figure 2E). When we
quantitated cell numbers, we found that the IFNGR−/−→WT
chimeras harbored significantly more neutrophils in the
CNS on days 10 and 15 after EAE induction (Figure 2F).
We then differentiated between the Ly6Clo and Ly6Chi
monocyte/macrophage populations and found that only the
Ly6Clo population was significantly increased on day 10
(Figures 2G,H). The Ly6Chi population consists of CCR2+
inflammatory macrophages (Geissmann et al., 2003). The
Ly6Clo population is comprised of microglial cells and non-
inflammatory or resident macrophages. When we examined
lesions in the chimera mice by immunofluorescence (Shriver
and Dittel, 2006), as expected, we were able to identify lesions
containing large numbers of CD11b+ myeloid cells in the
spinal cord (blue) that also contained T cells (TCRβ, green)
and neutrophils (red) in both chimeras (Figure 3). While we
observed lesions in the brain stem in both chimeras, only
the IFNGR−/−→WT chimeras contained large numbers of
neutrophils (Figure 3). Given that only the peripheral immune
system is devoid of IFNGR signaling in the IFNGR−/−→WT
chimeras, these data indicate that peripheral immune cells are a
major regulator of the influx of neutrophils into the brain stem.
Whether this is due to production of ELR+ CXC chemokines
by infiltrating cells is not known, but is plausible given that
macrophages have been reported to produce CXCL1 and CXCL2
(Kanayama et al., 2015). Other studies have identified astrocytes
and NG2+ glial cells as sources of ELR+ CXC chemokines,
particularly in response to IL-17 signaling (Kang et al., 2010,
2013; Simmons et al., 2014; Ding et al., 2015).
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FIGURE 3 | Neutrophils are present in spinal cord lesions in both WT→
WT and IFNGR−/−→WT chimeras, but are only present in the brain
stem of IFNGR−/−→WT chimeras. The generation of BM chimeras and
EAE induced were performed as for Figures 1, 2, respectively. On day 10 after
EAE induction mice were perfused and frozen sections (10µm) of the spinal
cord and brain stem were generated as described (Shriver and Dittel, 2006).
The sections were stained with anti-mouse CD11b (blue), anti-mouse TCRβ
(green), and anti-mouse Ly6C (red) and visualized by confocal microscopy.
Scale bar: 20µm.
A Role for Neutrophils in MS?
While mouse studies in EAE clearly demonstrate an essential role
for granulocytes (neutrophils) in EAE pathogenesis this has been
more difficult to demonstrate in MS. Established MS lesions are
largely devoid of neutrophils prompting many to conclude that
neutrophils do not play a role in MS. However, the paucity of
neutrophils inMS lesions is likely due the fact that neutrophils are
short-lived once they enter tissues and undergo oxidative burst
and degranulate. Little is known regarding neutrophil function
in MS patients. While one study reported that neutrophils from
MS patients exhibited depressed functions (Podikoglou et al.,
1994), this finding was not consistent with two other reports
demonstrating that neutrophils expressing a primed phenotype
were increased in the peripheral blood of MS patients (Ziaber
et al., 1998; Naegele et al., 2012). Recently, it was shown that the
neutrophil-to-lymphocyte ratio was significantly higher in MS
patients as compared to controls, with the ratio being the highest
in MS patients in relapse (Demirci et al., 2015). In addition,
logistic regression analysis with dichotomous expanded disability
status scale (EDSS) score, which measures MS disability, revealed
that a high neutrophil-to-lymphocyte ratio was a predictor of
disability progression (Demirci et al., 2015). Additional evidence
supporting a role for neutrophils in MS patients is their increase
in serum CXCL8 (IL-8), which is a chemoattractant for both
monocytes and neutrophils in humans (Lund et al., 2004). In
a second report, elevated plasma levels of CXCL5, an ELR+
CXC chemokine, was reported in relapsing MS during new
lesion formation (Rumble et al., 2015). Of importance, is that
new lesion formation was not associated with increased levels
of the lymphocyte and monocyte chemoattracting CXCL10 or
CCL2, respectively (Rumble et al., 2015). In this same study,
plasma levels of CXCL1, CXCL5 and neutrophil elastase directly
correlated with the EDSS score and the cumulative MRI lesion
volume on T1 weighted sequences indicating tissue damage
and axonal loss (Rumble et al., 2015). In addition, CXCL5
and neutrophil elastase expression correlated with T2 weighted
sequences that measure overall brain volume (Rumble et al.,
2015). These findings in MS patients are consistent with the
finding by the same group that neutrophils are essential to relapse
in SJL/J mice (Carlson et al., 2008). More recently postmortem
tissue from a MS patient affected by relapse following cessation
of natalizumab therapy showed a prominent neutrophil presence
in areas of BBB leakage (Aube et al., 2014). Overall, the above
cumulative studies provide strong evidence that neutrophils play
a pathogenic role in MS relapse. However, neutrophils are not
necessarily a prerequisite for MS as demonstrated by two case
reports in whichMS patients exhibited low neutrophil counts due
to either autoimmune neutropenia or a long-standing idiopathic
neutropenia (Kozuka et al., 2003; Munzel et al., 2013). While the
mechanism whereby neutrophils contribute to MS pathogenesis
are not clearly understood, they likely involve their generation
of reactive oxygen species that induce oxidative stress, which is
considered a major driver of MS pathogenesis (Gilgun-Sherki
et al., 2004).
Concluding Remarks
Since the failure of IFN-γ as a therapeutic treatment for MS,
we have uncovered much about the biology of IFN-γ and its
receptor. It is now appreciated that within the confines of the
CNS, the anti-inflammatory properties of IFN-γ largely outweigh
its pro-inflammatory mechanisms. Given the pleiotropic effects
of IFN-γ and the fact that its receptor is expressed by virtually
all cell types, in retrospect, it is not surprising that its systemic
administration failed to have therapeutic benefit in MS. In the
many EAE studies conducted in IFN-γ−/− and IFNGR−/− mice
using a multitude of animal models it has become clear that
one major mechanism whereby IFN-γ controls the severity and
nature of EAE is by regulating the recruitment of neutrophils
into the CNS. Specifically, we propose that encephalitogenic
T cells enter the CNS and via their production of IL-17 and
other inflammatory mediators induce the expression of ELR+
CXC chemokines by infiltrating macrophages and CNS resident
astrocytes and NG2+ glial cells. Neutrophils in turn migrate
into the CNS and produce oxygen radicals leading to the
opening of the BBB and tissue damage. IFN-γ production by
polarized Th1 cells or Th17 cells that have converted to Th1 cells
directly downregulate the expression of ELR+ CXC chemokines
restricting neutrophil migration into the CNS. These data also
provide strong evidence that neutrophils must play an essential
role in the pathogenesis of MS. Given that neutrophils can
modulate disease by a variety of mechanisms including their
well-established role in disruption of the BBB they should be
considered as a therapeutic target in MS. In particular, the
targeting of neutrophils during relapses is well justified.
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